S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
The Stock That's Brining Lithium Back To America! (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
The Stock That's Brining Lithium Back To America! (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
The Stock That's Brining Lithium Back To America! (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
S&P 500   4,283.85
DOW   33,573.28
QQQ   354.84
High Dividend REITs: Are They an Ideal Way to Diversify?
Laser breakthrough could send stock soaring 2,467% (Ad)
Dollar General May Create an Opportunity for Patient Investors
Is Frontline's 20% Dividend Too Good To Be True?
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks (Ad)
3 Reasons The Wayfair Rally Is Way Overdone
Wheat prices jump following collapse of major dam in southern Ukraine
The Stock That's Brining Lithium Back To America! (Ad)
Here’s What’s Driving the Price of Carvana Higher
Stock market today: Asian stocks mixed as Wall St inches toward bull market
NASDAQ:ARVN

Arvinas (ARVN) Stock Forecast, Price & News

$23.54
+0.39 (+1.68%)
(As of 06/6/2023 ET)
Compare
Today's Range
$22.56
$23.85
50-Day Range
$21.73
$28.54
52-Week Range
$21.21
$58.58
Volume
289,690 shs
Average Volume
465,614 shs
Market Capitalization
$1.26 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.33

Arvinas MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
186.0% Upside
$67.33 Price Target
Short Interest
Healthy
7.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.02mentions of Arvinas in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($6.70) to ($7.81) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

631st out of 981 stocks

Pharmaceutical Preparations Industry

304th out of 462 stocks


ARVN stock logo

About Arvinas (NASDAQ:ARVN) Stock

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Receive ARVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter.

ARVN Stock News Headlines

Arvinas (NASDAQ:ARVN) Sets New 52-Week Low at $21.86
Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
Our #1 Laser Stock for May
The Pentagon calls laser weapons "the future." This small cap just won a $1.65 billion contract to make them. See why this stock could soar 2,476% >>>
Where Arvinas Stands With Analysts
Arvinas (NASDAQ:ARVN) Posts Quarterly Earnings Results
Arvinas to Present at Stifel Targeted Oncology Day
See More Headlines

ARVN Price History

ARVN Company Calendar

Last Earnings
5/05/2023
Today
6/06/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ARVN
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$67.33
High Stock Price Forecast
$95.00
Low Stock Price Forecast
$27.00
Forecasted Upside/Downside
+186.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Net Income
$-282,500,000.00
Net Margins
-227.86%
Pretax Margin
-208.63%

Debt

Sales & Book Value

Annual Sales
$131.40 million
Book Value
$10.61 per share

Miscellaneous

Free Float
52,036,000
Market Cap
$1.26 billion
Optionable
Not Optionable
Beta
1.75

Key Executives

  • John G. HoustonJohn G. Houston
    President, Chief Executive Officer & Director
  • Lisa Sinclair
    Senior Vice President-Corporate Operations
  • Sean A. CassidySean A. Cassidy
    Chief Financial Officer
  • Ian TaylorIan Taylor
    Chief Scientific Officer
  • Ronald PeckRonald Peck
    Chief Medical Officer













ARVN Stock - Frequently Asked Questions

Should I buy or sell Arvinas stock right now?

16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ARVN shares.
View ARVN analyst ratings
or view top-rated stocks.

What is Arvinas' stock price forecast for 2023?

16 Wall Street research analysts have issued 1 year price objectives for Arvinas' stock. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they expect the company's share price to reach $67.33 in the next twelve months. This suggests a possible upside of 186.0% from the stock's current price.
View analysts price targets for ARVN
or view top-rated stocks among Wall Street analysts.

How have ARVN shares performed in 2023?

Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN shares have decreased by 31.2% and is now trading at $23.54.
View the best growth stocks for 2023 here
.

Are investors shorting Arvinas?

Arvinas saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 3,670,000 shares, a decrease of 10.9% from the April 30th total of 4,120,000 shares. Based on an average daily trading volume, of 445,800 shares, the short-interest ratio is currently 8.2 days. Currently, 8.0% of the shares of the stock are short sold.
View Arvinas' Short Interest
.

When is Arvinas' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ARVN earnings forecast
.

How were Arvinas' earnings last quarter?

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings results on Friday, May, 5th. The company reported ($1.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by $0.05. The business earned $32.50 million during the quarter, compared to the consensus estimate of $27.74 million. Arvinas had a negative net margin of 227.86% and a negative trailing twelve-month return on equity of 50.85%. The firm's quarterly revenue was up 22.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.20) EPS.

What other stocks do shareholders of Arvinas own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

When did Arvinas IPO?

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

What is Arvinas' stock symbol?

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Who are Arvinas' major shareholders?

Arvinas' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include FMR LLC (10.71%), BlackRock Inc. (8.38%), EcoR1 Capital LLC (6.96%), Price T Rowe Associates Inc. MD (4.71%), ArrowMark Colorado Holdings LLC (2.94%) and State Street Corp (2.07%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy, Timothy M Shannon and Timothy M Shannon.
View institutional ownership trends
.

How do I buy shares of Arvinas?

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arvinas' stock price today?

One share of ARVN stock can currently be purchased for approximately $23.54.

How much money does Arvinas make?

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.26 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.66) on an earnings per share basis.

How many employees does Arvinas have?

The company employs 280 workers across the globe.

How can I contact Arvinas?

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.

This page (NASDAQ:ARVN) was last updated on 6/7/2023 by MarketBeat.com Staff

My Account -